A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown
Locations
Bethesda
Sponsor
Protocol Number
GBT440-031
Cancer Diagnosis
To Learn More Call
201-510-0910